Compare OFG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | VCEL |
|---|---|---|
| Founded | 1964 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2012 | 1996 |
| Metric | OFG | VCEL |
|---|---|---|
| Price | $50.49 | $47.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $45.17 | ★ $57.75 |
| AVG Volume (30 Days) | 415.9K | ★ 704.3K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 8.27 | ★ 60.00 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $11.56 | $19.40 |
| Revenue Next Year | $1.29 | $18.24 |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $35.71 | $28.95 |
| 52 Week High | $51.42 | $48.75 |
| Indicator | OFG | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 66.57 |
| Support Level | $48.67 | $32.47 |
| Resistance Level | $50.66 | N/A |
| Average True Range (ATR) | 0.95 | 1.74 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 58.01 | 76.25 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.